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Malotilate (diisopropyl-1,3-dithiol-2-ylidenemalonate; structure shown in Figure 1 ) is a synthetic agent that has been reported to prevent the progress of experimental liver injury induced by various hepatotoxicants, such as carbon tetrachloride, dimethylnitrosamine, bromobenzene, and acetaminophen (1) (2) (3) (4) (5) . Using malotilate as a lead compound, a series of structural derivatives were synthesized for clinical use in the Figure 1 ) has been found to retain the most remarkable hepatoprotective activity with no apparent toxicity (6) . The compound is currently under phase II clinical trial for use in humans as a hepatoprotectant. Both malotilate (7) and YH439 (8) have recently been found to markedly suppress the expression of cytochrome P450 2E1 (CYP2E1) which is responsible for metabolism of many low molecular weight drugs and carcinogens (9) . Since CYP2E1 is inducible by ethanol consumption, this isoform has been implicated in the intoxication of chronic alcoholics who are much more susceptible to liver injury induced by certain drugs including acetaminophen (10) .
In consideration of roles of cytochrome P-450-dependent mixed-function oxidases in metabolic activation as well as detoxification of chemical carcinogens of diverse categories, compounds that modulate the activity of these enzymes may influence processes of chemically-induced tumorigenesis. As part of our study directed towards evaluating possible cancer chemopreventive properties of YH439, we initially sought to examine its effect on hepatotoxicity, mutagenicity, and tumorigenicity of vinyl carbamate (VC), a proximate hepatocarcinogen that is known to be preferentially activated by CYP2E1 (11) to an ultimate electrophilic and tumorigenic epoxide (12) .
YH439 was provided by the Yuhan Research Center (Kunpo-si, Korea). VC was synthesized as described previously (12) . Trioctanoin was obtained from the Pfaltz and Bauer, Inc. (Stamford, CT). 12-O-Tetradecanoylphorbol-13-acetate (TPA) was supplied from the Chemsyn Science Laboratory (Lenexa, KS). Reagents for determination of serum enzymes were purchased from the Sigma Chemical Co. (St Louis, MO). Male Sprague-Dawley rats (Teklad/Halan Sprague-Dawley, Madison, WI) of~4 weeks of age were gavaged with YH439 (200 mg/kg body wt) suspended in trioctanoin 2 days, 1 day and 4 h prior to a single i.p. injection of VC (125 mg/kg) in saline or the vehicle alone. Blood was collected 24 h after VC dosing and the activities of serum enzymes were measured using kits from the Sigma Chemical Co., according to the instructions provided. Liver biopsy specimens were fixed in buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) for histopathological examination. Statistical differences in serum enzyme activities between treated and untreated groups were determined by Student's unpaired t-test. The Salmonellamicrosome assay was performed according to the liquid preincubation method of Maron and Ames (13), using Salmonella typhimurium TA1535 as a tester strain. The data were corrected for the numbers of spontaneous revertants. To conduct the two stage skin carcinogenesis experiment, the dorsal region of female CD-1 mice (~7 weeks old) was shaven with an electric clipper. Groups of 20-25 mice were gavaged with YH439 (150 mg/kg body wt) or diallyl sulfide (200 mg/kg) suspended in trioctanoin or with the vehicle alone, 1 day and 2 h prior to a single topical application of VC (11.5 µmol) in 0.2 ml acetone. Control animals received acetone in lieu of the carcinogen. Beginning one week after the initiation, all mice were subjected to topical applications of 2.5 µg TPA, twice weekly until the termination of the experiment. The mice were reshaven as necessary and papillomas were enumerated bimonthly. Mutations at codons 12 or 61 of the H-ras protooncogene in skin tumors were analyzed by in vitro amplification of DNA using the polymerase chain reaction, followed by restriction fragment length polymorphism after digestion with restriction enzymes as described elsewhere (14) . Table I summarizes the activities of two serum enzymes, viz, aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT) which are markers of hepatic damage. Sera of rats treated with a single i.p. dose of VC alone exhibited significantly high activities of these enzymes, compared with control animals given vehicle alone. Pretreatment of rats with oral dosages of YH439 completely protected against VCinduced hepatic damage as revealed by the pronounced decrease in the serum enzyme activities (Table I) . Severity of hepatic damage was confirmed by histopathological examination of liver sections under light microscopy. Liver sections from rats treated with VC exhibited centrilobular necrosis and extensive hemorrhage (Figure 2A) , whereas no such abnormalities were observed in the livers of rats given three oral doses of YH439 prior to the carcinogen challenge ( Figure  2B ). YH439 alone did not produce any hepatotoxicity as reflected by the normal liver histomorphology ( Figure 2C ) as well as the control levels of serum enzyme activities (Table I) .
The effect of YH439 on the mutagenic activity of VC was examined in S.typhimurium TA1535. As summarized in Table II, YH439 exhibited dose-related protection against VCinduced his ϩ reversion in these bacteria. Oral administration of YH439 (150 mg/kg body wt) 1 day and 2 h before the topical application of VC (11.5 µmol) resulted in~60% reduction in formation of mouse skin tumors at 22 weeks after Prevention of experimental liver injury VC was incubated with the bacteria (1-2ϫ10 9 ) and microsomes (1 mg protein) from male Sprague-Dawley rats in a final vol. of 0.6 ml 0.1 M potassium phosphate buffer (pH 7.4) in the absence or presence of the given amount of YH439. After preincubation at 37°C for 30 min, the mixtures were diluted with soft agar, plated onto minimal glucose agar plates and further incubated for 48 h to allow the development of his ϩ revertant colonies. promotion, which was comparable to that attained with diallyl sulfide pretreatment (Table III) . Under these experimental conditions, none of the mice given YH439 alone developed tumors. Activating mutations in codon 61 of H-ras gene were identified in all of the DNA samples from randomly selected VC-induced tumors. YH439 pretreatment did not alter the frequency or spectrum of H-ras mutations induced by VC (data not shown).
The results of this study demonstrate that pretreatment of male Sprague-Dawley rats with YH439 by gavage completely protects against the acute hepatotoxic effects of VC. The attenuation by YH439 of VC-induced hepatic injury appears to be related to its ability to inhibit CYP2E1 that mediates the activation of this carcinogen to an ultimate electrophilic and tumorigenic metabolite, vinyl carbamate epoxide (VCO). In line with this possibility, Kim and his co-workers (7) reported that malotilate, when given to male Sprague-Dawley rats by gavage, decreased the levels of CYP2E1 protein in liver microsomes. Subsequent work by Jeong et al. (8) has shown that oral administration of the structurally related malotilate derivative YH439 leads to rapid and specific suppression of CYP2E1-linked catalytic activity in rat liver microsomes with a concomitant decrease in the hepatic CYP2E1 mRNA level.
Recently, certain organosulfur-containing compounds have been found to be potent and effective cancer chemopreventive agents. Examples are diallyl sulfide in garlic (15) (16) (17) (18) and sulforaphane (4-methylsulfinylbutyl isothiocyanate) isolated from broccoli (19) . One of the plausible mechanisms of chemoprotective action of diallyl sulfide has been ascribed to its selective inhibition of CYP2E1 (20) . Sulforaphane was found to induce phase II detoxification enzymes, such as NAD(P)H:quinone oxidoreductase and glutathione S-transferase (21), thereby facilitating the removal of carcinogens or their active metabolites. In addition, sulforaphane has been reported to inhibit cytochrome P450 2E1 (CYP2E1) (22) , an important isoform that is responsible for activation of a wide array of carcinogens and mutagens. Besides naturally occurring organosulfur compounds, certain synthetic sulfur-containing substances have been shown to suppress experimental carcinogenesis. Of particular interest are sulindac and oltipraz. Sulindac, which was originally developed as a non-steroidal antiinflamammtory drug, has been found to inhibit experimental colon and lung tumorigenesis in rodents (23, 24) . Because of its ability to induce regression of colonic adenomas (25) , chemoprevention trials with sulindac have been underway for patients with familial adenomatous polyposis. The antischistosomal drug oltipraz also exhibits striking chemopreventive activities against chemically induced carcinogenesis in various animal models (26) (27) (28) . It also ameliorates hepatic damage induced by aflatoxin B 1 , acetaminophen, or carbon tetrachloride (29) (30) (31) . The chemoprotective properties of oltipraz have been attributed primarily to the induction of glutathione S-transferase and NAD(P)H:quinone reductase (32), which play key roles in protection against chemically-induced toxicity and carcinogenesis. Furthermore, recent studies have shown that oltipraze can inhibit phase I xenobiotic metabolizing enzyme (33, 34) , such as cytochrome P450 1A2 and 3A4 isoforms that catalyze the activation of aflatoxin B 1 to an electrophilic epoxide metabolite. Sulforaphane and oltipraz can thus influence the metabolism of carcinogens via inhibition of phase I or induction of phase II enzymes, which may account for their chemopreventive or chemoprotective effects. By analogy, YH439 has a dual effect on the carcinogen metabolism. In addition to inhibiting CYP2E1 [8] , oral administration of this synthetic dithiol malonate to rats gave rise to significant elevation of the phase II enzymes: in our preliminary studies, the activities of hepatic glutathione S-transferase and quinone reductase were elevated 32% and 76%, respectively in rats after administration of YH439 (200 mg/kg) by gavage for 30 days (unpublished data). Taken together, the capability of YH439 to retard the metabolic activation of carcinogens and/or to facilitate their removal from the body would provide rationale for application of this compound to cancer chemoprevention (35) .
VC can interact with target cell DNA to form covalently bound adducts via metabolic activation to the ultimate electrophilic and carcinogenic epoxide VCO, which may lead to mutations in certain protooncogens. Activation of H-ras protooncogene through mutation in a specific codon has been frequently observed in a wide range of human cancers as well as in chemically-induced tumors in experimental animals. The types of ras gene mutations are generally associated with the known metabolic activation pathways and DNA binding characteristics of carcinogens, and can be affected by specific chemopreventive agents. YH439 pretreatment did not alter the frequency or spectrum of H-ras mutations induced by VC. Since the pattern of ras mutations is determined in part by the nature of the ultimate electrophilic form of a given carcinogen, the above results suggest that the observed chemopreventive effects of YH439 against VC are mediated through suppression of their activation and subsequent DNA binding without deviating the metabolic pathways involved.
In conclusion, YH439 pretreatment produced substantial protection aganst VC-induced liver damage, mutagenesis and tumorigenesis, presumably through repression of CYP2E1 responsible for activating this hepatocarcinogen and/or via induction of phase II detoxification enzymes. Further investigations should follow to evaluate the chemopreventive activity of YH439 in diverse animal models.
